PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35551662-13	2022	Antibody-Drug Conjugates (ADC) constitute the only FDA-approved immunotherapy to treat AML with Gemtuzumab Ozogamicin, a CD33-specific ADC used in CEBPalpha-mutated AML.	OZOGAMICIN	107-117	CCAAT enhancer binding protein alpha	Homo sapiens	147-156